Literature DB >> 1939774

Cardiac tumors: assessment with Gd-DTPA enhanced MR imaging.

M Funari1, N Fujita, W W Peck, C B Higgins.   

Abstract

Previous studies have shown the value of MR imaging for the identification of cardiac masses. The distinction of intramural tumors from normal myocardium may be equivocal because of the similarity of signal intensity between tumor and normal myocardium on ECG-gated SE images. The purpose of this study was to assess the role of Gd-DTPA for improving the contrast between cardiac tumors and myocardium. Four patients with established or suspected cardiac tumors were imaged with a 1.5 T imager. The T1-weighted images (TR = RR interval, TE = 20-30 ms) were obtained before and immediately after the intravenous injection of Gd-DTPA, at a dosage of 0.1 mmol/kg. Tumors were identified in three patients. All tumors were isointense to the myocardium in precontrast images but demonstrated differential enhancement relative to myocardium after the administration of Gd-DTPA. Two tumors were hyperintense relative to myocardium, and the third was mostly hypointense, surrounded by a hyperintense rim. In the remaining case, no tumor was found and the myocardium was homogeneously enhanced on postgadolinium images. Gadolinium DTPA can produce differential enhancement of tumor from normal myocardium and therefore demonstrate intramural masses.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1939774

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  14 in total

Review 1.  Imaging sequences in cardiovascular magnetic resonance: current role, evolving applications, and technical challenges.

Authors:  El-Sayed H Ibrahim
Journal:  Int J Cardiovasc Imaging       Date:  2012-03-25       Impact factor: 2.357

2.  Magnetic resonance imaging in the management of pericardial disease.

Authors:  Monvadi B Srichai; Leon Axel
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-12

3.  Cardiac metastasis of a renal cell adenocarcinoma investigated by cardiac magnetic resonance imaging.

Authors:  A Deetjen; G Conradi; S Möllmann; A Kluge; C W Hamm; T Dill
Journal:  Clin Res Cardiol       Date:  2006-07-14       Impact factor: 5.460

4.  Metastatic carcinoid tumor obstructing left ventricular outflow.

Authors:  George S Chrysant; Douglas A Horstmanshof; Uma M Guniganti
Journal:  Tex Heart Inst J       Date:  2011

Review 5.  [Magnetic resonance imaging and spiral computed tomography in the diagnosis and follow-up of adults with congenital heart and vessel disease].

Authors:  H Kaemmerer; T Ibrahim; M Schwaiger; J Hess
Journal:  Herz       Date:  1999-06       Impact factor: 1.443

6.  MR first pass perfusion of benign and malignant cardiac tumours-significant differences and diagnostic accuracy.

Authors:  K U Bauner; S Sourbron; M Picciolo; C Schmitz; D Theisen; T A Sandner; M F Reiser; A M Huber
Journal:  Eur Radiol       Date:  2011-08-26       Impact factor: 5.315

7.  Evaluation by electron beam computed tomography of intracardiac masses suspected by transoesophageal echocardiography.

Authors:  E Mousseaux; A Hernigou; M Azencot; M Sapoval; M Auguste; J C Gaux
Journal:  Heart       Date:  1996-09       Impact factor: 5.994

Review 8.  Imaging the pericardium: appearances on ECG-gated 64-detector row cardiac computed tomography.

Authors:  S M O'Leary; P L Williams; M P Williams; A J Edwards; C A Roobottom; G J Morgan-Hughes; N E Manghat
Journal:  Br J Radiol       Date:  2010-03       Impact factor: 3.039

9.  Role of magnetic resonance imaging for evaluation of tumors in the cardiac region.

Authors:  Tatsuro Kaminaga; Thoru Takeshita; Izumi Kimura
Journal:  Eur Radiol       Date:  2003-01-18       Impact factor: 5.315

10.  Simultaneous gallium-67 citrate and technetium-99m sestamibi SPET in a case of myocardial lymphoma: comparison with echocardiography before and after chemotherapy.

Authors:  L Kostakoglu; N Roistacher; H Kalaigian; S M Larson; H Abdel-Dayem
Journal:  Eur J Nucl Med       Date:  1994-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.